Quest PharmaTech Inc. (CVE:QPT – Get Free Report) rose 40% on Friday . The stock traded as high as C$0.04 and last traded at C$0.04. Approximately 1,172,033 shares changed hands during mid-day trading, an increase of 1,485% from the average daily volume of 73,952 shares. The stock had previously closed at C$0.03.
Quest PharmaTech Price Performance
The company has a market capitalization of C$5.07 million, a P/E ratio of -1.50 and a beta of 0.14. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35. The business has a 50 day simple moving average of C$0.03 and a 200-day simple moving average of C$0.03.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Recommended Stories
- Five stocks we like better than Quest PharmaTech
- Pros And Cons Of Monthly Dividend Stocks
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- What is a Death Cross in Stocks?
- Top 3 ETFs to Hedge Against Inflation in 2025
- What Are the U.K. Market Holidays? How to Invest and Trade
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
